SynthesisThe Cochrane database of systematic reviews2011
Artesunate versus quinine for treating severe malaria.
Synthesis in The Cochrane database of systematic reviews, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Pooled it
- Artemether for severe malaria.The Cochrane database of systematic reviews · 2014Pooled it
- Trial
- Intravenous artesunate plus Artemisnin based Combination Therapy (ACT) or intravenous quinine plus ACT for treatment of severe malaria in Ugandan children: a randomized controlled clinical trial.BMC infectious diseases · 2017Trial
- Efficacy of a novel sublingual spray formulation of artemether in African children with Plasmodium falciparum malaria.Antimicrobial agents and chemotherapy · 2015Trial
- Pharmacokinetics and pharmacodynamics of intravenous artesunate during severe malaria treatment in Ugandan adults.Malaria journal · 2012Trial
- Pre-referral rectal artesunate is no "magic bullet" in weak health systems.BMC medicine · 2023Article
- Severe malaria. Current concepts and practical overview: What every intensivist should know.Intensive care medicine · 2020Review
- Determinants of post-malarial anemia in African children treated with parenteral artesunate.Scientific reports · 2019Article
- Level of knowledge among health care providers on preparation of injectable artesunate for treatment of severe malaria in public health facilities in Tanzania.BMC research notes · 2019Article
- Dynamic deformability of Plasmodium falciparum-infected erythrocytes exposed to artesunate in vitro.Integrative biology : quantitative biosciences from nano to macro · 2013Article
- Severe Plasmodium vivax malaria among sudanese children at New Halfa Hospital, Eastern Sudan.Parasites & vectors · 2012Article
- Post-treatment haemolysis in severe imported malaria after intravenous artesunate: case report of three patients with hyperparasitaemia.Malaria journal · 2012Article
- A novel carbon monoxide-releasing molecule fully protects mice from severe malaria.Antimicrobial agents and chemotherapy · 2012Article
- Successful oral therapy for severe falciparum malaria: the World Health Organization criteria revisited.The American journal of tropical medicine and hygiene · 2012Article
- Time to switch from quinine.Sudanese journal of paediatrics · 2012Article
- Treatment of imported severe malaria with artesunate instead of quinine--more evidence needed?Malaria journal · 2011Article
- Responding to the evidence for the management of severe malaria.Tropical medicine & international health : TM & IH · 2011Article
- Hypoglycaemia and severe Plasmodium falciparum malaria among pregnant Sudanese women in an area characterized by unstable malaria transmission.Parasites & vectors · 2011Article
Corrections and comments
- Updated by
- Update of
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere malaria results in over a million deaths every year, most of them in children aged under five years and living in sub-Saharan Africa. This review examines whether treatment with artesunate, instead of the standard treatment quinine, would result in fewer deaths and better treatment outcomes.
objectivesTo compare artesunate with quinine for treating severe malaria. SEARCH STRATEGY: We searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library), MEDLINE, EMBASE, LILACS, ISI Web of Science, the metaRegister of Controlled trials (mRCT), conference proceedings, and reference lists of articles to November 2010. SELECTION CRITERIA: Randomized controlled trials comparing intravenous, intramuscular, or rectal artesunate with intravenous or intramuscular quinine for treating adults and children with severe malaria who are unable to take medication by mouth. DATA COLLECTION AND ANALYSIS: Two authors independently assessed the eligibility and risk of bias of trials, and extracted and analysed data. The primary outcome was all-cause death. Dichotomous outcomes were summarized using risk ratios (RR) and continuous outcomes by mean differences (MD). Where appropriate, we combined data in meta-analyses. MAIN
resultsEight trials enrolling 1664 adults and 5765 children are included in this review.Treatment with artesunate significantly reduced the risk of death both in adults (RR 0.61, 95% Confidence Interval (CI) 0.50 to 0.75; 1664 participants, five trials) and children (RR 0.76, 95% CI 0.65 to 0.90; 5765 participants, four trials)In children, treatment with artesunate increased the incidence of neurological sequelae at the time of hospital discharge. The majority of these sequelae were transient and no significant difference between treatments was seen at later follow up. AUTHORS'
conclusionsThe evidence clearly supports the superiority of parenteral artesunate over quinine for the treatment of severe malaria in both adults and children and in different regions of the world.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.